- Report
- August 2025
- 180 Pages
Global
From €3130EUR$3,545USD£2,713GBP
€3478EUR$3,939USD£3,015GBP
- Report
- August 2025
- 199 Pages
Global
From €3130EUR$3,545USD£2,713GBP
€3478EUR$3,939USD£3,015GBP
- Report
- June 2025
- 185 Pages
Global
From €3973EUR$4,500USD£3,444GBP
- Report
- May 2024
- 129 Pages
Global
From €5738EUR$6,499USD£4,974GBP
- Report
- April 2023
- 110 Pages
Global
From €4194EUR$4,750USD£3,635GBP
Ferumoxytol is a hematological drug used to treat iron deficiency anemia. It is an intravenous iron replacement therapy that is administered in two doses. Ferumoxytol is a superparamagnetic iron oxide nanoparticle that is composed of a ferric oxide core and a dextran coating. It is used to replenish iron stores in the body and is indicated for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.
Ferumoxytol is a relatively new drug in the hematological drug market and is gaining traction due to its efficacy and safety profile. It is a convenient and cost-effective alternative to other intravenous iron replacement therapies.
Some companies in the Ferumoxytol market include AMAG Pharmaceuticals, Inc., Fresenius Kabi USA, LLC, and Vifor Pharma Ltd. Show Less Read more